[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530666":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":37,"responsibleParty":88,"collaborators":90,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":98,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":10,"studyType":109,"phases":10,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cases",null,"Moderate-severe OSA (defined as AHI ≥15 events\u002Fhour)",[13],"Device: Positive Airway Pressure",{"label":15,"type":10,"description":16,"interventionNames":10},"Controls","No OSA (defined as AHI \\\u003C5 events\u002Fhour)",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DEVICE","Positive Airway Pressure","Case participants will use Positive Airway Pressure (PAP) treatment as part of routine clinical care.",[9],[24],{"name":25,"affiliation":5,"role":26},"Allan I Pack, MBChB, PhD","PRINCIPAL_INVESTIGATOR",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Colleen M Walsh, MS","CONTACT","215-614-0047","walshco@pennmedicine.upenn.edu",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Kristie C Nguyen","215-615-4112","kristie.nguyen@pennmedicine.upenn.edu",[38,58,73],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"The Ohio State University - Martha Morehouse Medical Pavilion, Suite 2600","RECRUITING","Columbus","Ohio","43221","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-82.99879,39.96118,{"lat":50,"lon":49},[53,57],{"name":54,"role":30,"phone":55,"phoneExt":10,"email":56},"Ulysses J Magalang, MD","614-292-4307","ulysses.magalang@osumc.edu",{"name":54,"role":26,"phone":10,"phoneExt":10,"email":10},{"facility":5,"status":40,"city":59,"state":60,"zip":61,"country":44,"countryCode":45,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Philadelphia","Pennsylvania","19104",{"type":47,"coordinates":63},[64,65],-75.16362,39.95238,{"lat":65,"lon":64},[68,69,72],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},{"name":25,"role":30,"phone":70,"phoneExt":10,"email":71},"215-746-4806","pack@pennmedicine.upenn.edu",{"name":25,"role":26,"phone":10,"phoneExt":10,"email":10},{"facility":74,"status":40,"city":75,"state":10,"zip":10,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"University of Iceland","Reykjavik","Iceland","IS",{"type":47,"coordinates":79},[80,81],-21.89541,64.13548,{"lat":81,"lon":80},[84,87],{"name":85,"role":30,"phone":10,"phoneExt":10,"email":86},"Thorarinn Gislason, MD","thorarig@landspitali.is",{"name":85,"role":26,"phone":10,"phoneExt":10,"email":10},{"type":89,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[91,94],{"name":92,"class":93},"National Institutes of Health (NIH)","NIH",{"name":95,"class":93},"National Heart, Lung, and Blood Institute (NHLBI)","100530666","micrornas-as-biomarkers-for-obstructive-sleep-apnea-100530666",false,"NCT06189755","MicroRNAs as Biomarkers for Obstructive Sleep Apnea","MIR-OSA","Inclusion Criteria for Cases:\n\n* age 18-75 years\n* moderate-severe OSA (defined as AHI ≥15 events\u002Fhour)\n* willing to accept PAP therapy\n\nInclusion Criteria for Controls:\n\n* age 18-75 years\n* no OSA (defined as AHI \\\u003C5 events\u002Fhour)\n\nExclusion Criteria for Cases:\n\n* current use of PAP or other OSA treatments\n* home oxygen therapy\n* recent changes (within 3 months) to BP medications among those who are on these medications\n* presence of Cheyne-Stokes Respiration (CSR) in sleep study\n* predominantly central sleep apnea (AHI≥15 events\u002Fhour, with \\>50% central events)\n* pregnancy\n* clinical history of chronic kidney disease (Stage 5) requiring dialysis, or renal transplant\n* organ transplantation\n* self-reported sleep duration less than 5 hours per night on weeknights (work nights)\n* current night shift work\n\nExclusion Criteria for Controls:\n\n* home oxygen therapy\n* pregnancy\n* clinical history of chronic kidney disease (Stage 5) requiring dialysis, or renal transplant\n* organ transplantation\n* self-reported sleep duration less than 5 hours per night on weeknights (work nights)\n* current night shift work","ALL","18 Years","75 Years",{"count":107,"type":108},500,"ESTIMATED","OBSERVATIONAL","Although obstructive sleep apnea (OSA) is a common disorder, there are no blood biomarkers for identification and management of these patients. This project will study microRNAs in order to develop and validate blood biomarkers that are specific to OSA, useful for identification of cases with OSA, reflective of efficacy of therapy, and able to predict blood pressure response to treatment of OSA.",[112],"Obstructive Sleep Apnea",[114,115,116],"Sleep Apnea","Biomarkers","Blood pressure","2026-07-30",{"date":119,"type":120},"2026-08-03","ACTUAL",{"date":122,"type":120},"2024-04-01",{"date":124,"type":108},"2028-04-30",{"name":5,"class":6},3]